The Valley Desk

NCT03350815 · Interventional trial

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

Overall registry status Completed

Phase 4

Conditions Ankylosing Spondylitis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov